{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-24-000008","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.602612+00:00","generated_at":"2026-06-06T00:48:33.931561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad Q4 sales down 6.7% YoY; Life Science segment declines 19.1%","bullets":["Q4 net sales $681.2M, down 6.7% YoY; currency-neutral sales down 7.7%.","Life Science segment sales $291.1M, down 19.1% YoY on broad-based weakness.","Clinical Diagnostics segment sales $389.0M, up 5.3% YoY on diabetes and quality control demand.","Net income $349.7M ($12.14 diluted EPS) vs $827.7M ($27.78) a year ago, impacted by Sartorius fair value changes.","CEO cites ongoing biopharma weakness; expects gradual recovery in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-24-000008","json":"https://secwatch.observer/filing/0000012208-24-000008.json","markdown":"https://secwatch.observer/filing/0000012208-24-000008.md","text":"https://secwatch.observer/filing/0000012208-24-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/0000012208-24-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/bio-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:48:33.931561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2276b7cd30438a7434f93f45d5c6477b289f4f66","claim":"BIO-RAD LABORATORIES, INC. reported the quarter ended December 31, 2023 results: revenue $681.2 million, net income $349.7 million, EPS $12.14 per share, on a diluted basis.","evidence_excerpt":"Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.7 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the fourth quarter of 2023 versus approximately $13.4 million in the year ago period. Excluding COVID-related sales, revenue decreased 6.0 percent on a currency-neutral basis. Life Science segment net sales for the fourth quarter were $291.1 million, a decline of 19.1 percent compared to the same period in 2022. On a currency-neutral basis, Life Science segment sales decreased by 19.9 percent compared to the same quarter in 2022. Excluding COVID-related sales, Lif","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220824000008/0000012208-24-000008-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$681.2 million"},{"label":"Net income","value":"$349.7 million"},{"label":"EPS","value":"$12.14 per share, on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}